ADAmangul Duisenova

Amangul Duisenova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amangul Duisenova has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • OROPHARYNGEAL CARRIAGE OF NEISSERIA MENINGITIDIS AMONG STUDENTS AT ASFENDIYAROV KAZAKH NATIONAL MEDICAL UNIVERSITY, ALMATY, KAZAKHSTAN

    by M.A. Smagul, L.K. Kasabekova, A.S. Esmagambetova, G.T. Nukenova, A.M. Sataeva, A.S. Mutalieva, A.T. Kalykova, Zh. Soltanay, A.M. Sadykova, R.ZH. Baykhozhaeva, et al.

    Background. Invasive meningococcal disease (IMD) caused by Neisseria meningitidis remains a serious public health concern, particularly among unvaccinated young people living in organized settings such as student dormitories. Objective. The aim of the study was to assess the prevalence of Neisseria meningitidis carriage among students at the S.D.Asfendiyarov Kazakh National Medical University during the initial screening, to determine changes in carriage rates after 7–8 months, and to identify potential epidemiological risk factors. Materials and methods. An observational cross-sectional study was conducted among first-year students of Asfendiyarov Kazakh National Medical University. Examinations were performed at two time points: before moving into dormitories (Stage I) and after 7–8 months (Stage II). Oropharyngeal swabs were collected from 648 students at baseline and 617 at follow-up by trained laboratory staff. Detection of N. meningitidisand its serogroups was performed using PCR. Statistical analysis was carried out in STATA software. Associations between carriage and potential risk factors were assessed using X2 or Fisher’s exact tests, with statistical significance set at p < 0.05. Results. A total of 588 students (mean age 18 years) were included in the analysis. None of the carriers had clinical manifestations of disease. At Stage I, N. meningitidis carriage was detected in 18 students (3%). At Stage II, the carriage rate increased to 43 students (7%). At baseline, male sex (p = 0.011) and living with three or more roommates (p= 0.025) were significantly associated with carriage. Smoking status, frequency of visiting public places, and having a partner were not associated with meningococcal carriage. During follow-up, reported symptoms showed no statistically significant association with PCR-confirmed carriage. Conclusion. The prevalence of N. meningitidis carriage increased markedly during the first months of university attendance. These findings highlight the importance of implementing preventive measures in student populations to reduce the risk of IMD transmission. Введение. Инвазивная менингококковая инфекция (ИМИ), вызванная Neisseria meningitidis, остаётся серьёзной проблемой общественного здравоохранения, особенно среди невакцинированных молодых людей, проживающих в организованных коллективах, таких как студенческие общежития. Цель исследования. Оценить распространённость носительства Neisseria meningitidis среди студентов Казахского национального медицинского университета имени С.Д. Асфендиярова при первичном обследовании, определить изменение частоты носительства через 7–8 месяцев и выявить возможные эпидемиологические факторы риска. Материалы и методы.Проведено обсервационное кросс-секционное исследование среди студентов первого курса Казахского национального медицинского университета имени С. Асфендиярова. Обследование проводилось в две временные точки: до заселения в общежитие (I этап) и через 7–8 месяцев (II этап). Материалом исследования служили мазки из ротоглотки. Пробы были получены у 648 студентов на I этапе и у 617 — на II этапе. Выявление N. meningitidis и его серогрупп осуществлялось методом ПЦР. Статистический анализ выполнен с использованием программы STATA с применением критериев X2 и точного критерия Фишера; уровень значимости принят равным p <0,05. Результаты. В анализ включены данные 588 студентов со средним возрастом 18 лет. Клинические проявления ИМИ у носителей отсутствовали. На I этапе носительство N. meningitidis выявлено у 18 студентов (3%), на II этапе — у 43 (7%). Факторами, статистически значимо ассоциированными с носительством при первичном обследовании, были мужской пол (p= 0,011) и проживание с тремя и более соседями (p = 0,025). Курение, посещение общественных мест и наличие партнёра статистически значимой связи с носительством не имели. При повторном обследовании выявленные жалобы также не ассоциировались с носительством. Выводы. Частота носительства N. meningitidis существенно возрастает в первые месяцы обучения в вузе, что подчёркивает необходимость внедрения профилактических мероприятий в студенческой среде. Кіріспе. Neisseria meningitidis қоздырғышымен шақырылатын инвазивті менингококкты инфекция (ИМИ) қоғамдық денсаулық сақтау үшін өзекті мәселе болып...

  • An open, observational, non-interventional, multicenter study of the effect of Kagocel® on the quality of life of patients with acute respiratory viral infections in realworld clinical practice in the Republic of Kazakhstan

    by B. N. Kosherova, S. A. Kulzhanova, A. K. Duisenova, E. S. Zhunusov, G. N. Abuova

    Relevance. Acute respiratory infections are the leading cause of disease worldwide. Kagocel® is a synthetic antiviral agent indicated for influenza and other acute respiratory viral infections (ARVI). It induces the production of interferon, thereby enhancing the immune response to viral pathogens. Objective. To evaluate changes in quality of life and symptom dynamics when prescribing Kagocel® to patients with ARVI. Materials and methods. This open, multicenter, observational, non-interventional study enrolled 1000 adult patients, 467 with mild and 533 with moderate ARVI. All patients were prescribed Kagocel® tablets for 4 days within 24–72 h from the ARVI symptom onset. Results. In patients with mild ARVI, a statistically significant (p Conclusion. The oral administration of Kagocel® to ambulatory patients with mild to moderate ARVI was effective and safe; therefore, it may be routinely recommended.

  • Open Access

    Post-COVID-19 fatigue: A cross-sectional study

    by Arailym Abilbayeva, Anel Tarabayeva, Elmira Bitanova, Akbope Myrkassymova, Amangul Duisenova, Moldir Sadykova, Uldana Sakhadin

    Aim: To evaluate the prevalence of post-infection fatigue (PVFS) over one year after COVID-19. Material and methods: 165 people who had COVID-19 more than a year ago were interviewed. A Fatigue Assessment Scale was used to assess the degree of fatigue. Chemiluminescent analysis was carried out to detect antibodies to Epstein-Barr Virus (EBV) antigens. For statistical analysis Fisher's exact test and Spearman correlation were conducted. Results: Among people with PVFS, there were 4.1 times more women than men (80.4% vs. 19.6%), people over 45 years old (76%), and people who needed hospitalization for COVID-19 (76%). The average fatigue duration was 573±18,3 days. Among individuals without PVFS, there were significantly more individuals under the age of 45 compared with the group of individuals with PVFS (40% and 24%, respectively, p=0.007) and there were significantly more individuals who did not need hospitalization compared with the group of individuals with PVFS (52% vs. 24%, p=0.005). EBV reactivation was determined in almost half of the individuals with PVFS (48%), while none of the individuals without PVFS had EBV reactivation. A statistically significant negative mean correlation was found between the duration of PVFS and the severity of PVFS (r=-0.357, p=0.007). A statistically significant negative correlation was found between the PVFS duration and the PVFS severity (r=-0.357, p=0.007). Conclusion: PVFS is a prevalent symptom after COVID-19. The duration of PVFS can reach and not be limited to 1.5 years. PVFS is more typical of women, people over 45 years of age and people who have had moderate and severe COVID-19. Over time, the severity of PVFS decreases. Key words: COVID-19, post-infection fatigue, Epstein-Barr virus

  • Open Access

    Clinical and laboratory characteristics of COVID-19 in hospitalized hypertensive patients

    by A. A. Abilbayeva, A. S. Tarabayeva, G. M. Idrisova, R. A. Yegemberdiyeva, A. K. Abdrakhmanova, A. M. Sadykova, A. K. Duisenova

    Objective. To identify clinical and laboratory differences of COVID-19 in patients with hypertension (HTN), as well as to identify factors associated with its severe course in these patients. Design and methods. A retrospective analysis of case histories of 940 patients with COVID-19 was performed. Statistical analysis was carried out by the method of contingency tables using Pearson's Chi-square test with Bonferroni correction, multiple logistic regression analysis and ROC-analysis were also applied. Results. The group of patients with COVID-19 and HTN showed a number of significant differences compared with the group of patients without HTN history. The study group was characterized by higher rates of females, people over 65, patients with severe COVID-19. They were more likely to have diabetes mellitus, coronary heart disease, and chronic kidney disease. On admission, in the group of HTN patients, leukocytosis and elevated blood glucose levels were more common, as well as pneumonia, shortness of breath and low saturation (p < 0,05). Multivariate logistic regression analysis showed that the presence of coronary heart disease (odds ratio (OR) = 3,492, 95 % confidential interval (CI): 2,016-6,048), leukocytosis (OR = 1,376, 95 % CI: 1,540-7,703), thrombocytopenia (OR = 1,779, 95 % CI: 1,031-3,071) and low SpO2 saturation (OR = 3,265, 95 % CI: 1,996-5,341) were associated with severe COVID-19 in hypertensive patients. ROC-analysis showed that the combination of the identified factors increases power of their association with the severe COVID-19 in HTN patients (AUC = 0,766). Conclusions. 1. Some indicators of hospitalized COVID-19 patients with HTN are different compared to patients with no HTN history. 2. Factors associated with severe COVID-19 in individuals with HTN do not differ from those in the general population of COVID-19 patients. 3. Severe COVID-19 in patients with HTN was strongly associated with the low SpO2 saturation and the presence of concomitant coronary heart disease.

  • Open Access

    Рост числа случаев остеонекрозов в «Эпоху Covid-19»: случайность или закономерность?

    by Ч.т. Баймухамедов, А.к. Ботабекова, Э.г. Гасымов, Ж.ш. Лесова, Б.ш. Абшенов, Н.н. Курманали, А.к. Дуйсенова

    Четвертый год пандемии коронавирусной инфекции Covid-19, вызванной SARS Cov-2 (Severe acute respiratory syndrome coronavirus-2, coronavirus infectious disease), унес более 6 800 000 жизней. Практические врачи (прежде всего ревматологи, травматологи, врачи общей практики) все чаще сталкиваются с новой проблемой – остеонекрозом (асептическим некрозом) головки бедренной кости, тяжелым инвалидизирующим заболеванием. Пандемия Covid-19 привела к повышению частоты развития асептических некрозов. Возможно, мы стоим на пороге эпидемии остеонекрозов, учитывая огромное количество переболевших Covid-19 людей и получавших глюкокортикоиды при терапии SARS-Cov-2. По данным статистики «Медицинского центра болезней суставов г. Шымкент» за последние 3 года наблюдается почти трехкратный рост данной патологии. Цель статьи – проанализировать данные литературы и собственные случаи, а также обсудить возможную связь между остеонекрозом и Covid-19, в том числе с лечением коронавирусной инфекции Covid-19 глюкокортикоидами. 6 800 000 астам өмірді қиған SARS-Cov-2 (Severe acute respiratory syndrome coronavirus-2, Covid-19) індет пандемиясының төртінші жылы аяқталуда. Тәжірибелік дәрігерлер (ең алдымен ревматологтар, травматологтар, жалпы тажірибелік дәрігерлер) ауыр мүгедектікке алып келуші патология – жамбас сүйегі ұршығының остеонекрозы (асептикалық некроз) деген жаңа мәселені жиі кездестіруде. Covid-19 пандемиясы асептикалық некроздардың даму жиілігіне алып келеді. «Шымкент қаласының буын аурулары медициналық орталығында» соңғы 3 жылда осы патологияның үш есе өсуі байқалуда. Мүмкін, пандемия SARS-Cov-2 асептикалық некроз эпидемиясына алып келуде. Мақаланың мақсаты әдебиеттерде көрсетілген деректермен өз тәжірибемізде кездескен науқастардағы остеонекроздарды талдау, сонымен қатар, Covid-19 және остеонекроз арасындағы мүмкін болған байланысты, оның ішінде SARS-Cov-2-ні глюкокортикоидтармен емдеуді талқылау. The fourth year of the SARS-Cov-2 (Severe Acute Respiratory Syndrome Coronavirus-2, Covid-19) pandemic is started, which has already claimed more than 6,800,000 lives, is coming to an end. Сlinicians (primarily rheumatologists, traumatologists, general practitioners) are more often facing a new problem – osteonecrosis (aseptic necrosis) of the femoral head, a severe disabling disease. The Covid-19 pandemic has led to an increase in the incidence of aseptic necrosis. We may be on the threshold of an epidemic of osteonecrosis, given the big amount of people who recovered from Covid-19 and were given glucocorticoids as part of SARS-Cov-2 therapy. Over the past 3 years there has been an almost threefold increase of cases in the «Medical Center for Joint Diseases in Shymkent». It is likely that the SARS-Cov-2 pandemic is leading to an epidemic of aseptic necrosis, both due to direct exposure to the virus and because of therapy. The purpose of the article is to analyze literature data and own cases of patients with osteonecrosis and to discuss a possible relationship between osteonecrosis and Covid-19, including the treatment of SARS-Cov-2 with glucocorticoids.

  • Open Access

    Clinical and laboratory COVID-19 features in hospitalized patients with concomitant diabetes mellitus type 2: A retrospective study

    by Arailym Abilbayeva, Anel Tarabayeva, Gulzhana Idrisova, Aigul Abdrakhmanova, Ainur Sadykova, Ravilya Yegemberdiyeva, Amangul Duisenova

    Objective: To investigate the prevalence of diabetes mellitus in comorbidity structures and its effect on the clinical course in hospitalized COVID-19 patients in south region of Kazakhstan. Material and methods: A retrospective analysis of data from 918 patients with COVID-19 treated at the City Clinical Infectious Diseases Hospital was carried out. Pearson's Chi-square test and Student's t-test were conducted. Results: In Kazakhstan, diabetes mellitus occupies the second position in the structure of comorbidities in patients with COVID-19 with a share of 20%. Diabetes mellitus in patients most often occurs in combination with cardiovascular diseases and arterial hypertension (20.3% and 16.3%, respectively). Combination of diabetes mellitus, arterial hypertension and other diseases was detected in 72.4% of patients. Combination of diabetes mellitus, cardiovascular and other diseases was detected in 32.5%. In diabetes mellitus patients, COVID-19 was more severe, the hospital stay was longer, and patients over 60 years of age suffered. These patients had a combination of diabetes mellitus with arterial hypertension, obesity, and cardiovascular diseases. Hyperglycemia, elevated blood pressure, rapid breathing, and low saturation were more common for these patients. Conclusion: Diabetes mellitus ranks second in the structure of comorbidities in COVID-19 in the south region of Kazakhstan and is characterized by a combination with cardiovascular diseases, arterial hypertension and obesity. In patients with diabetes, COVID-19 is more severe, which affects the length of stay in the hospital, the mortality rate and the need for transfer to the Intensive Care Unit.


  • Vector-borne and zoonotic infections and their relationships with regional and socioeconomic statuses: An ID-IRI survey in 24 countries of Europe, Africa and Asia

    by Fatma Nurhayat Saydam, Hakan Erdem, Handan Ankarali, Manar Ezz El-Arab Ramadan, Nagwa Mostafa El-Sayed, Rok Civljak, Natalia Pshenichnaya, Ruxandra Valentina Moroti, Fatemeh Moradi Mahmuodabad, Agah Victor Maduka, et al.